search
Back to results

Kisspeptin Influence on Glucose Homeostasis

Primary Purpose

Impaired Glucose Tolerance, Hypogonadism

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
kisspeptin 112-121
Insulin Resistance Test
Placebo
Sponsored by
Stephanie B. Seminara, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Impaired Glucose Tolerance focused on measuring insulin regulation in pregnancy, kisspeptin

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion/Exclusion Criteria:

History:

  • normal pubertal development
  • stable weight for previous three months
  • no active illicit drug use,
  • no history of a medication reaction requiring emergency medical care,
  • no difficulty with blood draws.

Physical examination:

• systolic BP < 140 mm Hg, diastolic < 90 mm Hg,

Laboratory studies: (per MGH reference ranges)

  • normal hemoglobin, unless hypogonadal then no lower than 0.5 gm/dL below the lower limit of the reference range for normal women (as men and women with hypogonadism have lower hemoglobin levels off of treatment)
  • hemoglobin A1C < 6.5%
  • BUN, creatinine not elevated
  • AST, ALT < 3x upper limit of normal
  • negative serum pregnancy test (for all women)
  • no hyperlipidemia by fasting lipid panel

Additional Criteria by Study Population

Healthy Men:

  • normal body mass index (BMI between 18.5-25)
  • no history of chronic disease, except well controlled thyroid disease
  • no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine or seasonal allergy medications is acceptable.
  • no history of diabetes in a first degree relative.

Healthy Women:

  • normal body mass index (BMI between 18.5-25)
  • no history of chronic disease, except well controlled thyroid disease,
  • no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine or seasonal allergy medications is acceptable.
  • no history of diabetes in a first degree relative,
  • no use of contraceptive pills, patches or vaginal rings within last 4 weeks.
  • regular menstrual cycles

Postmenopausal Women:

  • body mass index (BMI between 18.5-30)
  • no history of chronic disease except thyroid disease, and osteoporosis,
  • no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine, osteoporosis medications or seasonal allergy medications is acceptable,
  • no history of diabetes in a first degree relative,
  • normal activate protein C resistance screen,
  • if applicable, able to undergo appropriate washout from hormone therapy.

Men and Women with Impaired Glucose Tolerance (IGT):

  • diagnosis of impaired glucose tolerance by oral glucose tolerance test,
  • all medical conditions well-controlled.

Men and Women with Hypogonadism

  • diagnosis of hypogonadism,
  • all other medical conditions well-controlled,
  • if applicable, able to undergo appropriate washout from hormone therapy.

Sites / Locations

  • Massachusetts General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Kisspeptin and Insulin Resistance Test

Placebo and Insulin Resistance Test

Arm Description

Intravenous (IV) administration of kisspeptin 112-121; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose

IV administration of fluids that contain no study drug; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose

Outcomes

Primary Outcome Measures

Average difference in area under the curve of insulin in response to a mixed meal tolerance test
Compares difference on and off kisspeptin

Secondary Outcome Measures

Average difference in area under the curve of glucose in response to a mixed meal tolerance test
Compares difference on and off kisspeptin
Average difference in area under the curve of glucagon-like peptide 1 in response to a mixed meal tolerance test
Compares difference on and off kisspeptin

Full Information

First Posted
November 1, 2016
Last Updated
July 17, 2023
Sponsor
Stephanie B. Seminara, MD
search

1. Study Identification

Unique Protocol Identification Number
NCT02953834
Brief Title
Kisspeptin Influence on Glucose Homeostasis
Official Title
Kisspeptin Influence on Glucose Homeostasis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 18, 2017 (Actual)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
August 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Stephanie B. Seminara, MD

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this study is to learn about how a naturally occurring hormone called kisspeptin affects blood sugar and insulin levels.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Impaired Glucose Tolerance, Hypogonadism
Keywords
insulin regulation in pregnancy, kisspeptin

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
413 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Kisspeptin and Insulin Resistance Test
Arm Type
Experimental
Arm Description
Intravenous (IV) administration of kisspeptin 112-121; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
Arm Title
Placebo and Insulin Resistance Test
Arm Type
Placebo Comparator
Arm Description
IV administration of fluids that contain no study drug; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
Intervention Type
Drug
Intervention Name(s)
kisspeptin 112-121
Other Intervention Name(s)
metastin 45-54
Intervention Description
Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours
Intervention Type
Other
Intervention Name(s)
Insulin Resistance Test
Intervention Description
Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Receive IV fluids for up to 16 hours that do not contain any study drug
Primary Outcome Measure Information:
Title
Average difference in area under the curve of insulin in response to a mixed meal tolerance test
Description
Compares difference on and off kisspeptin
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
Average difference in area under the curve of glucose in response to a mixed meal tolerance test
Description
Compares difference on and off kisspeptin
Time Frame
4 hours
Title
Average difference in area under the curve of glucagon-like peptide 1 in response to a mixed meal tolerance test
Description
Compares difference on and off kisspeptin
Time Frame
4 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion/Exclusion Criteria: History: normal pubertal development stable weight for previous three months no active illicit drug use, no history of a medication reaction requiring emergency medical care, no difficulty with blood draws. Physical examination: • systolic BP < 140 mm Hg, diastolic < 90 mm Hg, Laboratory studies: (per MGH reference ranges) normal hemoglobin, unless hypogonadal then no lower than 0.5 gm/dL below the lower limit of the reference range for normal women (as men and women with hypogonadism have lower hemoglobin levels off of treatment) hemoglobin A1C < 6.5% BUN, creatinine not elevated AST, ALT < 3x upper limit of normal negative serum pregnancy test (for all women) no hyperlipidemia by fasting lipid panel Additional Criteria by Study Population Healthy Men: normal body mass index (BMI between 18.5-25) no history of chronic disease, except well controlled thyroid disease no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine or seasonal allergy medications is acceptable. no history of diabetes in a first degree relative. Healthy Women: normal body mass index (BMI between 18.5-25) no history of chronic disease, except well controlled thyroid disease, no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine or seasonal allergy medications is acceptable. no history of diabetes in a first degree relative, no use of contraceptive pills, patches or vaginal rings within last 4 weeks. regular menstrual cycles Postmenopausal Women: body mass index (BMI between 18.5-30) no history of chronic disease except thyroid disease, and osteoporosis, no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine, osteoporosis medications or seasonal allergy medications is acceptable, no history of diabetes in a first degree relative, normal activate protein C resistance screen, if applicable, able to undergo appropriate washout from hormone therapy. Men and Women with Impaired Glucose Tolerance (IGT): diagnosis of impaired glucose tolerance by oral glucose tolerance test, all medical conditions well-controlled. Men and Women with Hypogonadism diagnosis of hypogonadism, all other medical conditions well-controlled, if applicable, able to undergo appropriate washout from hormone therapy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Margaret Lippincott, MD
Phone
617-726-8434
Email
mlippincott@partners.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Margaret Lippincott, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Margaret Lippincott, MD
Phone
617-726-8434
Email
mlippincott@partners.org
First Name & Middle Initial & Last Name & Degree
Margaret Lippincott, MD
First Name & Middle Initial & Last Name & Degree
Stephanie Seminara, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
After primary results are published, the authors will provide individuals participant data upon request as long as it does not conflict with state or Institutional regulations.

Learn more about this trial

Kisspeptin Influence on Glucose Homeostasis

We'll reach out to this number within 24 hrs